147 related articles for article (PubMed ID: 18463983)
1. HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma.
Sharif S; Ramanathan RK; Potter D; Cieply K; Krasinskas AM
Dig Dis Sci; 2008 Nov; 53(11):3026-32. PubMed ID: 18463983
[TBL] [Abstract][Full Text] [Related]
2. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma.
Stoecklein NH; Luebke AM; Erbersdobler A; Knoefel WT; Schraut W; Verde PE; Stern F; Scheunemann P; Peiper M; Eisenberger CF; Izbicki JR; Klein CA; Hosch SB
J Clin Oncol; 2004 Dec; 22(23):4737-45. PubMed ID: 15570074
[TBL] [Abstract][Full Text] [Related]
3. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
Bartlett JM; Campbell FM; Mallon EA
Am J Clin Pathol; 2008 Dec; 130(6):920-6. PubMed ID: 19019769
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
[TBL] [Abstract][Full Text] [Related]
5. HER2 gene copy number and breast cancer-specific survival.
Biserni GB; Engstrøm MJ; Bofin AM
Histopathology; 2016 Nov; 69(5):871-879. PubMed ID: 27271096
[TBL] [Abstract][Full Text] [Related]
6. HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer.
Chao WR; Lee MY; Lin WL; Chen CK; Lin JC; Koo CL; Sheu GT; Han CP
Hum Pathol; 2014 Apr; 45(4):810-6. PubMed ID: 24656091
[TBL] [Abstract][Full Text] [Related]
7. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy.
Bose S; Mohammed M; Shintaku P; Rao PN
Breast J; 2001; 7(5):337-44. PubMed ID: 11906444
[TBL] [Abstract][Full Text] [Related]
8. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
[TBL] [Abstract][Full Text] [Related]
9. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
Moelans CB; de Weger RA; van Diest PJ
Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
[TBL] [Abstract][Full Text] [Related]
10. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer.
Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Kato H
Int J Cancer; 2003 Jan; 103(1):61-6. PubMed ID: 12455054
[TBL] [Abstract][Full Text] [Related]
11. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma.
Watters AD; Going JJ; Cooke TG; Bartlett JM
Breast Cancer Res Treat; 2003 Jan; 77(2):109-14. PubMed ID: 12602909
[TBL] [Abstract][Full Text] [Related]
12. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
[TBL] [Abstract][Full Text] [Related]
13. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C
J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.
Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY
Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787
[TBL] [Abstract][Full Text] [Related]
15. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.
Downs-Kelly E; Yoder BJ; Stoler M; Tubbs RR; Skacel M; Grogan T; Roche P; Hicks DG
Am J Surg Pathol; 2005 Sep; 29(9):1221-7. PubMed ID: 16096413
[TBL] [Abstract][Full Text] [Related]
16. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
[TBL] [Abstract][Full Text] [Related]
17. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
18. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
Mueller RE; Parkes RK; Andrulis I; O'Malley FP
Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathologic significance of chromosome 17 polysomy in breast cancer].
Lü YL; Zhong M; Liu L; Wei LX; Zhao P
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):88-91. PubMed ID: 18681318
[TBL] [Abstract][Full Text] [Related]
20. Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients.
Moatter T; Aban M; Iqbal W; Azam I; Pervaiz A; Siddiqui F; Murad F; Pervez S
Asian Pac J Cancer Prev; 2011; 12(11):3069-73. PubMed ID: 22393991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
